{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:58:06Z","timestamp":1793213886318,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV.<\/jats:p>","DOI":"10.1038\/s41598-020-71225-1","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T10:03:50Z","timestamp":1598868230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies"],"prefix":"10.1038","volume":"10","author":[{"given":"Kimberley","family":"Steeds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yper","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian S.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Longet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Strecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Katharina","family":"Fehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Akoi","family":"Bore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara Raymond","family":"Koundouno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy Kader","family":"Konde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Hiscox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Pollakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"71225_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","volume":"377","author":"H Feldmann","year":"2011","unstructured":"Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849\u2013862 (2011).","journal-title":"Lancet"},{"key":"71225_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418\u20131425 (2014).","journal-title":"N. Engl. J. Med."},{"key":"71225_CR3","unstructured":"World Health Organization. Situation report - 10 June 2016, Accessed 07 Oct 2019. https:\/\/www.who.int\/csr\/disease\/ebola\/situation-reports\/archive\/en\/ (2016)."},{"key":"71225_CR4","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1128\/JVI.72.8.6442-6447.1998","volume":"72","author":"A Sanchez","year":"1998","unstructured":"Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 6442\u20136447 (1998).","journal-title":"J. Virol."},{"key":"71225_CR5","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1128\/JVI.01598-12","volume":"87","author":"O Martinez","year":"2013","unstructured":"Martinez, O. et al. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. J. Virol. 87, 3324\u20133334 (2013).","journal-title":"J. Virol."},{"key":"71225_CR6","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","volume":"72","author":"RJ Wool-Lewis","year":"1998","unstructured":"Wool-Lewis, R. J. & Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines. J. Virol. 72, 3155\u20133160 (1998).","journal-title":"J. Virol."},{"key":"71225_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.virol.2010.02.029","volume":"401","author":"DJ Shedlock","year":"2010","unstructured":"Shedlock, D. J. et al. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401, 228\u2013235 (2010).","journal-title":"Virology"},{"key":"71225_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","volume":"174","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174, 938\u2013952 (2018).","journal-title":"Cell"},{"key":"71225_CR9","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1093\/infdis\/jiy316","volume":"218","author":"KL Warfield","year":"2018","unstructured":"Warfield, K. L. et al. Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms. J. Infect. Dis. 218, S553-s564 (2018).","journal-title":"J. Infect. Dis."},{"key":"71225_CR10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1016\/j.vaccine.2015.04.071","volume":"33","author":"EM Bentley","year":"2015","unstructured":"Bentley, E. M., Mather, S. T. & Temperton, N. J. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine 33, 2955\u20132962 (2015).","journal-title":"Vaccine"},{"key":"71225_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/fvl.13.60","volume":"8","author":"S Mather","year":"2013","unstructured":"Mather, S. et al. Current progress with serological assays for exotic emerging\/re-emerging viruses. Future Virol. 8, 745\u2013755 (2013).","journal-title":"Future Virol."},{"key":"71225_CR12","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1128\/jvi.64.11.5270-5276.1990","volume":"64","author":"KA Page","year":"1990","unstructured":"Page, K. A., Landau, N. R. & Littman, D. R. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64, 5270\u20135276 (1990).","journal-title":"J. Virol."},{"key":"71225_CR13","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","volume":"94","author":"A Takada","year":"1997","unstructured":"Takada, A. et al. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 14764\u201314769 (1997).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"71225_CR14","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1128\/jvi.74.10.4933-4937.2000","volume":"74","author":"SY Chan","year":"2000","unstructured":"Chan, S. Y., Speck, R. F., Ma, M. C. & Goldsmith, M. A. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol. 74, 4933\u20134937 (2000).","journal-title":"J. Virol."},{"key":"71225_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","volume":"77","author":"A Takada","year":"2003","unstructured":"Takada, A. et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77, 1069\u20131074 (2003).","journal-title":"J. Virol."},{"key":"71225_CR16","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","volume":"3","author":"NJ Sullivan","year":"2006","unstructured":"Sullivan, N. J. et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3, e177 (2006).","journal-title":"PLoS Med."},{"key":"71225_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.virusres.2015.12.019","volume":"213","author":"J Luczkowiak","year":"2016","unstructured":"Luczkowiak, J. et al. Specific neutralizing response in plasma from convalescent patients of Ebola virus disease against the West Africa Makona variant of Ebola virus. Virus Res. 213, 224\u2013229 (2016).","journal-title":"Virus Res."},{"key":"71225_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jix584","volume":"217","author":"AW Rimoin","year":"2018","unstructured":"Rimoin, A. W. et al. Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection. J. Infect. Dis. 217, 223\u2013231 (2018).","journal-title":"J. Infect. Dis."},{"key":"71225_CR19","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982\u201310992 (2015).","journal-title":"J. Virol."},{"key":"71225_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"71225_CR21","doi-asserted-by":"publisher","first-page":"25856","DOI":"10.1038\/srep25856","volume":"6","author":"Q Zhang","year":"2016","unstructured":"Zhang, Q. et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci. Rep. 6, 25856 (2016).","journal-title":"Sci. Rep."},{"key":"71225_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/fvl.15.106","volume":"11","author":"B King","year":"2016","unstructured":"King, B. et al. Technical considerations for the generation of novel pseudotyped viruses. Future Virol. 11, 47\u201359 (2016).","journal-title":"Future Virol."},{"key":"71225_CR23","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","volume":"73","author":"T Maruyama","year":"1999","unstructured":"Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024\u20136030 (1999).","journal-title":"J. Virol."},{"key":"71225_CR24","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","volume":"76","author":"PW Parren","year":"2002","unstructured":"Parren, P. W., Geisbert, T. W., Maruyama, T., Jahrling, P. B. & Burton, D. R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76, 6408\u20136412 (2002).","journal-title":"J. Virol."},{"key":"71225_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"71225_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3201\/eid1103.040906","volume":"11","author":"NJ Temperton","year":"2005","unstructured":"Temperton, N. J. et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11, 411\u2013416 (2005).","journal-title":"Emerg. Infect. Dis."},{"key":"71225_CR27","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1016\/j.vaccine.2009.07.079","volume":"27","author":"I Alberini","year":"2009","unstructured":"Alberini, I. et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27, 5998\u20136003 (2009).","journal-title":"Vaccine"},{"key":"71225_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jviromet.2010.02.009","volume":"165","author":"W Wang","year":"2010","unstructured":"Wang, W., Xie, H., Ye, Z., Vassell, R. & Weiss, C. D. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods 165, 305\u2013310 (2010).","journal-title":"J. Virol. Methods"},{"key":"71225_CR29","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3201\/eid1910.130728","volume":"19","author":"C Qiu","year":"2013","unstructured":"Qiu, C. et al. Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus. Emerg. Infect. Dis. 19, 1685\u20131687 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"71225_CR30","doi-asserted-by":"publisher","first-page":"7178","DOI":"10.1016\/j.vaccine.2009.09.024","volume":"27","author":"E Wright","year":"2009","unstructured":"Wright, E. et al. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine 27, 7178\u20137186 (2009).","journal-title":"Vaccine"},{"key":"71225_CR31","doi-asserted-by":"publisher","first-page":"42769","DOI":"10.1038\/srep42769","volume":"7","author":"J Nie","year":"2017","unstructured":"Nie, J. et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci. Rep. 7, 42769 (2017).","journal-title":"Sci. Rep."},{"key":"71225_CR32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1128\/JCM.03109-12","volume":"51","author":"N Kishishita","year":"2013","unstructured":"Kishishita, N., Takeda, N., Anuegoonpipat, A. & Anantapreecha, S. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. J. Clin. Microbiol. 51, 1389\u20131395 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"71225_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2018.01.003","volume":"254","author":"K Konduru","year":"2018","unstructured":"Konduru, K., Shurtleff, A. C., Bavari, S. & Kaplan, G. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test. J. Virol. Methods 254, 1\u20137 (2018).","journal-title":"J. Virol. Methods"},{"key":"71225_CR34","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108\u201310125 (2005).","journal-title":"J. Virol."},{"key":"71225_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1099\/vir.0.83386-0","volume":"89","author":"AM Owsianka","year":"2008","unstructured":"Owsianka, A. M. et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89, 653\u2013659 (2008).","journal-title":"J. Gen. Virol."},{"key":"71225_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.vaccine.2016.11.083","volume":"35","author":"DE Wilkinson","year":"2017","unstructured":"Wilkinson, D. E. et al. Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine 35, 1347\u20131352 (2017).","journal-title":"Vaccine"},{"key":"71225_CR37","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1073\/pnas.0509996103","volume":"103","author":"M Stremlau","year":"2006","unstructured":"Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5\u03b1 restriction factor. Proc. Natl. Acad. Sci. U.S.A. 103, 5514\u20135519 (2006).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"71225_CR38","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing Ebola viruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"71225_CR39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/fvl.15.87","volume":"10","author":"NJ Temperton","year":"2015","unstructured":"Temperton, N. J. & Page, M. Ebola virus: Pseudotypes, libraries and standards. Future Virol. 10, 1187\u20131189 (2015).","journal-title":"Future Virol."},{"key":"71225_CR40","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1128\/JVI.76.14.6865-6872.2002","volume":"76","author":"L Buonocore","year":"2002","unstructured":"Buonocore, L., Blight, K. J., Rice, C. M. & Rose, J. K. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76, 6865\u20136872 (2002).","journal-title":"J. Virol."},{"key":"71225_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.chom.2018.07.018","volume":"24","author":"J Jin","year":"2018","unstructured":"Jin, J. et al. Neutralizing antibodies inhibit chikungunya virus budding at the plasma membrane. Cell Host Microbe 24, 417-428.e415 (2018).","journal-title":"Cell Host Microbe"},{"key":"71225_CR42","doi-asserted-by":"publisher","first-page":"e1000060","DOI":"10.1371\/journal.ppat.1000060","volume":"4","author":"S Nelson","year":"2008","unstructured":"Nelson, S. et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4, e1000060 (2008).","journal-title":"PLoS Pathog."},{"key":"71225_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871\u2013875 (1997).","journal-title":"Nat. Biotechnol."},{"key":"71225_CR44","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","volume":"89","author":"E Wright","year":"2008","unstructured":"Wright, E. et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: A cross-species comparison. J. Gen. Virol. 89, 2204\u20132213 (2008).","journal-title":"J. Gen. Virol."},{"key":"71225_CR45","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","volume":"374","author":"ST Agnandji","year":"2016","unstructured":"Agnandji, S. T. et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647\u20131660 (2016).","journal-title":"N. Engl. J. Med."},{"key":"71225_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1750-2659.2007.00016.x","volume":"1","author":"NJ Temperton","year":"2007","unstructured":"Temperton, N. J. et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 1, 105\u2013112 (2007).","journal-title":"Influenza Other Respir. Viruses"},{"key":"71225_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jviromet.2014.09.021","volume":"210","author":"ST Mather","year":"2014","unstructured":"Mather, S. T., Wright, E., Scott, S. D. & Temperton, N. J. Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay based diagnostic kit. J. Virol. Methods 210, 51\u201358 (2014).","journal-title":"J. Virol. Methods"},{"key":"71225_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"71225_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71225-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:29:05Z","timestamp":1670347745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71225"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71225-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"2 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14289"}}